Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MLN0264 in GCC-positive pancreatic adenocarcinoma
NCT02202785Phase 2Terminated
- Sponsor
- Millennium Pharmaceuticals
- Start
- Jul 2014
- Primary completion
- Jan 2016
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of indusatumab vedotin in pancreatic adenocarcinoma (PDAC), sponsored by Millennium Pharmaceuticals. Started Jul 2014; status: terminated.
02
Drugs
indusatumab vedotin
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02202785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02202785.